Developing biotechnologies in organoids for liver cancer

Biomedical Technology Pub Date : 2024-11-26 DOI:10.1016/j.bmt.2024.100067

Yingzhe Hu , Zheng Peng , Mengdi Qiu , Lingling Xue , Haozhen Ren , Xingyu Wu , Xinhua Zhu , Yitao Ding

{"title":"Developing biotechnologies in organoids for liver cancer","authors":"Yingzhe Hu , Zheng Peng , Mengdi Qiu , Lingling Xue , Haozhen Ren , Xingyu Wu , Xinhua Zhu , Yitao Ding","doi":"10.1016/j.bmt.2024.100067","DOIUrl":null,"url":null,"abstract":"<div><div>Organoids, three-dimensional cellular constructs, have revolutionized in vitro culture by replicating the histological and physiological functions of organs, offering a model that closely mimics physiological conditions. Liver cancer presents a significant challenge due to its heterogeneity and the influence of the liver's microenvironment on therapeutic responses. Organoid technology addresses this complexity by simulating the tumor microenvironment in vitro, capturing the heterogeneity of liver cancer, and facilitating personalized treatment approaches. This study explores the integration of organoids in liver cancer research, focusing on genetic and phenotypic fidelity, disease modeling, and drug screening. We discuss the latest advancements in biotechnology, including CRISPR/Cas9, 3D bioprinting, and microfluidics, and their role in personalized medicine. Despite challenges in scalability and variability, organoids offer a promising avenue for liver cancer research and precision oncology, with the potential to transform our understanding and treatment of this disease.</div></div>","PeriodicalId":100180,"journal":{"name":"Biomedical Technology","volume":"9 ","pages":"Article 100067"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedical Technology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949723X2400045X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Organoids, three-dimensional cellular constructs, have revolutionized in vitro culture by replicating the histological and physiological functions of organs, offering a model that closely mimics physiological conditions. Liver cancer presents a significant challenge due to its heterogeneity and the influence of the liver's microenvironment on therapeutic responses. Organoid technology addresses this complexity by simulating the tumor microenvironment in vitro, capturing the heterogeneity of liver cancer, and facilitating personalized treatment approaches. This study explores the integration of organoids in liver cancer research, focusing on genetic and phenotypic fidelity, disease modeling, and drug screening. We discuss the latest advancements in biotechnology, including CRISPR/Cas9, 3D bioprinting, and microfluidics, and their role in personalized medicine. Despite challenges in scalability and variability, organoids offer a promising avenue for liver cancer research and precision oncology, with the potential to transform our understanding and treatment of this disease.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

开发治疗肝癌的有机体生物技术

器官组织是一种三维细胞构建体，通过复制器官的组织学和生理功能，提供了一种近似生理条件的模型，从而彻底改变了体外培养。肝癌因其异质性和肝脏微环境对治疗反应的影响而成为一项重大挑战。类器官技术通过在体外模拟肿瘤微环境、捕捉肝癌的异质性和促进个性化治疗方法，解决了这一复杂性。本研究探讨了有机体在肝癌研究中的整合，重点关注遗传和表型保真度、疾病建模和药物筛选。我们讨论了生物技术的最新进展，包括CRISPR/Cas9、三维生物打印和微流控技术，以及它们在个性化医疗中的作用。尽管在可扩展性和可变性方面存在挑战，但器官组织为肝癌研究和精准肿瘤学提供了一个前景广阔的途径，有可能改变我们对这种疾病的理解和治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Biomedical Technology

CiteScore

4.10

自引率

0.00%

发文量